Graft-versus-leukaemia.
The high relapse rate after T-cell depleted bone marrow transplantation (BMT) for chronic myeloid leukaemia (CML) and the ability of donor lymphocyte transfusions to induce stable remission in patients relapsing after BMT has emphasized the importance of alloreacting donor T-lymphocytes in the graft-versus-leukaemia (GVL) effect in this disease. The mechanisms underlying the GVL response and its relationship with graft-versus-host disease are becoming better defined. There is accumulating evidence that the CD4+ T-cell plays a central role in the GVL response. The prominent role of GVL in the cure of CML after BMT may be associated with the fact that CML cells are strongly immunogenic. New transplant strategies are being devised to separate GVL from graft-versus-host reactions. Future developments focus on the identification of leukaemia-specific antigens and the amplification of T-cell responses against them.
Barrett
A J
AJ
Bone Marrow Transplant Unit, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 28092, USA.
van Rhee
F
F
D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D006087:Graft vs Host Reaction; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology / Q000628:therapy*; D012008:Recurrence; D014184:Transplantation, Homologous